Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma

Figure 5 Calibration curve and clinical utility analyses. A: Calibration curves of the nomogram on the training dataset. The Hosmer-Lemeshow test yielded a P value of 0.137 in the training dataset; B: Calibration curves of the nomogram on the validation dataset. The Hosmer-Lemeshow test yielded a P value of 0.165 in the validation dataset; C: Decision curve analysis for each model in the validation dataset. The Y-axis measures the net benefit, which is calculated by summing the benefits (true-positive findings) and subtracting the harms (false-positive findings). The decision curve showed that if the threshold probability is over 10%, the application of computed tomography-based radiomics nomogram to predict transarterial chemoembolization-refractoriness adds more benefit compared with the other scores/models. ART: Assessment for Retreatment with Transarterial Chemoembolization; ABCR: α-Fetoprotein, Barcelona Clinic Liver Cancer, Child-Pugh, and Response; CT: Computed tomography.